AlphaMeld Corporation and VedTechBio Forge Strategic AI-Powered Drug Discovery Alliance to Transform Metabolic and Liver Disease TherapeuticsGUILFORD, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- AlphaMeld Corporation, a global frontrunner in AI-powered drug discovery, and VedTechBio Research Pvt. Ltd., an emerging biopharma technology innovator specializing in translational research and program execution, today announced a multi-program strategic partnership to accelerate the development of novel therapies for metabolic and liver diseases, including obesity and rare hepatic disorders. The alliance will jointly advance up to three first-in-class therapeutic programs targeting urgent, unmet clinical needs in high-burden disease areas. This collaboration uniquely combines AlphaMeld’s AI-native drug discovery platform with VedTechBio’s translational infrastructure to compress timelines, reduce risk, and enhance capital efficiency—delivering superior value over traditional and first-generation AI drug discovery models.
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery PlatformLongstanding relationship strengthens innovation, providing diverse stakeholders access to advanced AI-driven insights to accelerate therapeutic discovery and development
